Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000635167 | SCV000756545 | uncertain significance | Early myoclonic encephalopathy | 2021-11-30 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 2046 of the JMJD1C protein (p.Glu2046Gln). This variant is present in population databases (rs376454657, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with JMJD1C-related conditions. ClinVar contains an entry for this variant (Variation ID: 529707). |
Ambry Genetics | RCV004025455 | SCV003609546 | uncertain significance | not specified | 2022-02-10 | criteria provided, single submitter | clinical testing | The c.6136G>C (p.E2046Q) alteration is located in exon 17 (coding exon 17) of the JMJD1C gene. This alteration results from a G to C substitution at nucleotide position 6136, causing the glutamic acid (E) at amino acid position 2046 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |